FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

FDA Needs More Postmarket Commitment Authority: Study

Researchers say Congress should consider giving FDA more authority to deal with companies that dont complete their postmarket commitments on time, inc...

latest-news-card-1
Human Drugs

2 Final Post-Approval Activity Guidances

FDA publishes two final guidances to facilitate the timely start and finish of medical device post-approval studies and postmarket surveillance.

latest-news-card-1
Medical Devices

Essure Postmarket Study Inadequate: FDA

FDA says Bayer is making inadequate progress in a postmarket surveillance study of its Essure birth control device.

latest-news-card-1
Human Drugs

Lilly Fast Track for Obesity Drug

FDA grants Eli Lilly a fast track designation for tirzepatide and its use for treating adults with obesity, or overweight with weight-related comorbi...

latest-news-card-1
Medical Devices

Medical Device User Fee Rates Set

Federal Register notice: FDA sets the medical device user fee rates and payment procedures for fiscal year 2023.

latest-news-card-1
Medical Devices

Aurora Spine SiLO Sacroiliac Device Cleared

FDA clears an Aurora Spine 510(k) for its SiLO TFX MIS Sacroiliac Joint Fixation System.

latest-news-card-1
Federal Register

Rx Drug User Fee Rates Set

Federal Register notice: FDA sets the rates for prescription drug user fees for fiscal year 2023.

latest-news-card-1
Medical Devices

Roches Pathway Test OKd for Low HER2

FDA approves a Roche PMA for the Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify metastatic breast cancer patients with low...

latest-news-card-1
Federal Register

Revatio sNDA for Pulmonary Hypertension Heads to Panel

Federal Register notice: FDA announces a 12/14 Cardiovascular and Renal Drugs Advisory Committee meeting to discuss a Viatris Specialty supplemental N...

latest-news-card-1
Federal Register

Panel to Discuss Heart Failure Drug

Federal Register notice: FDA announces a 12/13 Cardiovascular and Renal Drugs Advisory Committee meeting to review a Cytokinetics NDA for omecamtiv me...